Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established
- Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including pimecrolimus cream.
- Continuous long-term use of topical calcineurin inhibitors, including pimecrolimus cream, in any age group should be avoided, and application limited to areas of involvement with atopic dermatitis.
- pimecrolimus cream is not indicated for use in children less than 2 years of age.
FDA and Industry Communications
Patient Counseling Information
Updated January 2018